Activity assessment antimutagenic / mutagenic pomegranate (punica granatum l.) Through the in vivo test micronucleus

J. B Ferreira, B. H. B. Martins, W. M Tominaga, E. M. J. Lisboa, L. R. Albiero, A. C. Rosa, M. M. Sugui


Currently, Punica granatum Linn, known as pomegranate, has been introduced in the diet of the population because its therapeutic properties used as an alternative therapy capable of acting against various diseases, including cancer. The fruit is rich in phenolic compounds which give many biological effects including antioxidant activity. The present study aimed to evaluate the antimutagenic/mutagenic activity of aqueous fruit extract in bone marrow from male Swiss mice in DNA damage induced by the alkylating agent cyclophosphamide (CP) through the micronucleus test in vivo. Animals (five animals/group) were treated for a period of 15 consecutive days with aqueous extract of pomegranate (gavage) on day 15 received NaCl (0,9%) or CP (25 mg/kg) intraperitoneally and sacrificed after an interval of 24 hours and made the material his bone marrow for analysis of the frequency of micronucleated polychromatic erythrocytes (MNPCE). The results obtained from the study show a reduction in the number of MNPCE in animals pretreated with aqueous extract of pomegranate, under the study conditions described. There were no indications of mutagenic activity of the fruit on the DNA suggesting that future studies on the mechanism of action of specific compounds so that we can ensure the benefits of its use to the population.


Punica granatum. Antimutagenicity. Cyclophosphamide. Micronucleus Test.

Texto completo:



AJITH, T.A, JANARDHANAN, K.K. Cytotoxic and antitumor activities of a polypore macrofungus, Phellinus rimosus (Berk) Pilat. Journal Ethnopharmacol v. 84, p. 157-162, 2003.

CARDOSO, C. R. P. Atividade mutagênica e ativadora da resposta imune celular induzidas por Byrsonima crassa Niendezu e Byrsonima intermédia A.Juss. (Malpighiaceae). Dissertação (Mestrado em Análises Clínicas)- Faculdade de Ciências Farmacêuticas de Araquara, v. 591, f. 126, p. 3-7. Araraquara - São Paulo, Brasil, 2006.

DASSPRAKASH, M.V; ARUN, R.; ABRAHAM, S.K.; PREMKUMAR, K. In vitro and in vivo evaluation of antioxidant and antigenotoxic potential of Punica granatum leaf extract. Pharm Biol. v. 50(12), p. 1523-1530, 2012.

DELMANTO, R. D. et al. Antimutagenic effect of Agaricus blazei Murrill mushroon on the genotoxicity induced by cyclophosphamide. Mutation Research-Genetic Toxicology, v.496, n.1-2, p.15-21, 2001.

FERREIRA, F. G. et al. Avaliação de mutagenicidade e antimutagenicidade de diferentes frações e Pterogyne nitens (leguminosae) utilizando ensaio de micronúcleo em Tradescantia pallida. Revista Brasileira de Farmacognosia, vol. 19, n.1A, p.61-7, 2009.

GIL, A. C. Como elaborar projetos de pesquisa. Atlas, 4ª. Ed. São Paulo, 2002.

GUEMBAROVSKI, R. L.; COLUS, I. M. S. Câncer: uma doença genética. Genética na escola. v.3, n.1, p.4-7, 2008.

HOENSCH, H.P.; KIRCH, W. Potential role of flavonoids in the prevention of intestinal neoplasia: a review of their mode of action and their clinical perspectives. International of Journal Gastrointestinal of Cancer, v. 35(3), p. 187-195, 2005.

HORA, J. J.; MAYDEW, E. R.; LANSKY, E. P.; DWIVEDI, C. Chemopreventive effects of promeganate seed oil on skin tumor development in CD1 mice. Journal Med Food, v. 6(3), p. 157-161, 2003.

INCA - Instituto Nacional de Câncer 2012. Estimativa 2014: incidência de câncer no Brasil/Instituto Nacional de Câncer. Rio de Janeiro, 2014.

JARDINI, F. A.; MANCINI FILHO, J. Avaliação da atividade antioxidante em diferentes extratos da polpa e sementes da romã (Punica granatum, L.). Revista Brasileira de Ciências Farmacêutica. v. 43, n. 1, São Paulo, 2007.

JOHAR, D.; ROTH, J. C.; BAY, G. H.; WALKER, J. N.; KROCZAK, T. J.; LOS, M. Inflammatory response, reactive oxygen species, programmed (necrotic like and apoptotic) cell death and cancer. Ann Acad Med Bialostocensis. v. 49, p. 31-39, 2004.

KATSUBE N, IWASHITA K, TSUSHIDA T, YAMAKI K, KOBORI M. Induction of Apoptosis in Cancer Cells by Bilberry (Vaccinium myrtillus) and the Anthocyanins. J Agric Food Chem. v. 51(1), p. 68-75, 2003.

KAWAII, S.; LANSKY, E. P. Differentiation-promoting activity of promegranate (Punica granatum) fruit extracts in HL-60 huma promyelocytic leukemia cells. Journal Med. Food. v. 7(1), p. 13-18, 2004.

KIM, N.D.; MEHTA R.; YU, W.P.; NEEMAN, I.; LIVNEY, T.; AMICHAY, A.; POIRIER, D.; NICHOLIS, P.; KIRBY, A.; JIANG, W.G.; MANSEL, R.; RAMACHANDRAN, C.; RABI, T.; KAPLAN, B.; LANSKY, E. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Tr. v. 71, p. 203-217, 2002.

LANSKY E. P. et. Al. Possible synergistic prostate cancers suppression by anatomically discrete pomegranate fractions. Invest New Drug. v. 23, p. 11-20, Nova Iorque,2005.

LANSKY, E. P.; NEWMANN, R. A. Punica granatum (promegranate) and its potential for prevention and treatment of inflammation and cancer. Journal of Ethnopharmacology. v 109, p. 177 – 206, 2007.

LIU, R.H. Potential synergy of phytochemicals in cancer prevention: mechanism of action. American Society for Nutritional Sciences. v. 22, p. 3479-3485, Bethesda-MD, 2004.

MACGREGOR, J.T.; et al. Guidelines for the conduct of micronucleus assay in mammalian bone marrow erythrocytes. Mutation Research, v.189, p.103-12, 1987.

MARTINS, E. Plantas medicinais. Viçosa: UFV, p. 162-163, 1995.

NAVARRO V.; et. al. Antimicrobial evaluation of some plants used in Mexican traditional medicine for the treatment of infectious diseases. J Ethnopharmacol. v. 53, p. 143-147, Irlanda, 1996.

NEWMANN D. J.; CRAGG G. M.; SNADE K. M.; Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. v. 66, p. 1022-1037, 2003.

OLIVEIRA, L. P.; PINHEIRO, R. C.; VIEIRA, M. S.; PAULA, J. R.; BARA, M. T. F.; VALADARES, M. C. Atividade citotóxica e antiangiogênica de Punica granatum L., Punicaceae. Revista Brasileira de Farmacognosia. v. 20(2), p. 201-207, 2007.

PARK, O. J.; SURH, Y. J. Chemopreventive potential of epigalocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicology Letter. v.150, p. 43-56, 2004.

PEREIRA, C. A. B. Teste estatístico para comparar proporções em problemas de citogenética. Apud:

RABELLO-GAY, M. N., RODRIGUES M. A, La R., Mutagênese, teratogênese e carcinogênese: métodos e critérios de avaliação. Faculdade de Ciências Agronômicas - FCA. p.113-21, São Paulo,1991.

RAFFERTY, J. A.; 1996. Chemoprotection of normal tissues by transfer of drug resistence genes. Cancer Metast Rev. v. 15, p. 365-383, Nova Iorque, 1996.

SANTOS, E.H.B; BATISTA, F.P.R.; PEREIRA, L.M.; CAMPOS, L.M.A.; CASTRO, M.S.; AZEVÊDO, L.C. Composição físico-química dos frutos da romã (Punica granatum L.). V CONNEPI. Maceio-AL, 2010.

SEERAM, N. P.; ADAMS, L. S.; HENNING, S. M.; NIU, Y.; ZHANG, Y.; NAIR, M. G.; HEBER, D. In vitroantiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. Journal Nutr Biochem. v. 16, p. 360-367, 2005.

SHUKLA, S.; GUPTA, S. Dietary agents in the chemoprevention of prostate cancer. Nutritional and Cancer. v. 53(1), p.18-32, 2005.

SYED, D. N.; AFAQ, F.; MUKHTAR, H. Pomegranate derived products for cancer chemoprevention. Seminars in Cancer Biology. v. 17, p. 377–385, 2007.

TOI, M.; RAMACHANDRAN, C.; MELNICK, S. J.; IMAI, A.; FIFE, R. S.; CARR, R. E.; OIAKAWA, T.; LANSKY, E. P. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. Springer Netherlands. v. 6 (2), p. 121 – 128, Tóquio/Japão, 2003.

WILLETT, W. C. Balancing life-style and genomics research for disease prevention. Science. v. 296, p. 695-98, 2002.



  • Não há apontamentos.

Universidade Federal de Rondonópolis
Avenida dos Estudantes, 5055 - Cidade Universitária
Rondonópolis - MT, 78735-901